In a post-hoc analysis, cariprazine seemed to be effective in treating both depressive and manic episodes of bipolar I disorder across age groups.

Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...

For those who suspect they might have sleep apnoea, it could be useful to try the Epworth Sleepiness Scale questionnaire. The ...

A recent study published in the Journal of Psychopharmacology has offered encouraging preliminary findings for individuals ...

These days, it’s rare to hear conversations around climate change that have hope at the core, but for award-winning speaker ...

A new study, led by USC Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI), will explore structural alterations in the brains of people with bipolar disorder (BD), a chronic ...

The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...

"By analyzing the largest-ever worldwide data collection, Dr. Ching is discovering the brain circuitry involved in bipolar disorder and how commonly prescribed medications influence the brain.

Shares of GH Research PLC GHRS have rallied 54.8% in a week after the company, on Feb. 3, 2025, announced that it has met the ...

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...